Unlike pembrolizumab, a PD-1 inhibitor that specifically targets the obesity-driven PD-1/PD-L1 pathway, ipilimumab, a CTLA-4 inhibitor, modulates the immune response through a broader mechanism of action [31]. Here, CTLA4 is linked to obesity due to melanocortin 4 receptor deficiency.